Gland Pharma · NSE: GLAND · BSE: 543245
Q4 FY22 results · Jan–Mar 2022
Gland Pharma reported revenue from operations of ₹1,103.01 crore (up 24.2% from Q4 FY21) and net profit of ₹285.90 crore (up 9.8% from Q4 FY21) for Q4 FY22 (Jan–Mar 2022), on a consolidated basis.
| Item | Q4 FY22 | Q4 FY21 | YoY | Q3 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 1,103.01 | 887.75 | +24.2% | 1,063.33 | +3.7% |
| Other income | 65.23 | 47.21 | +38.2% | 45.67 | +42.8% |
| Total income | 1,168.25 | 934.96 | +25.0% | 1,108.99 | +5.3% |
| Profit before tax | 380.48 | 348.94 | +9.0% | 365.56 | +4.1% |
| Net profit for the period | 285.90 | 260.41 | +9.8% | 273.03 | +4.7% |
| EPS, basic (₹) | 17.40 | 15.93 | +9.2% | 16.62 | +4.7% |
| Net margin (%) | 25.9 | 29.3 | 25.7 |
| Item | Q4 FY22 | Q4 FY21 | YoY | Q3 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 1,103.01 | 887.75 | +24.2% | 1,063.33 | +3.7% |
| Other income | 65.23 | 47.21 | +38.2% | 45.67 | +42.8% |
| Total income | 1,168.25 | 934.96 | +25.0% | 1,108.99 | +5.3% |
| Profit before tax | 380.56 | 348.99 | +9.0% | 365.92 | +4.0% |
| Net profit for the period | 285.98 | 260.45 | +9.8% | 273.38 | +4.6% |
| EPS, basic (₹) | 17.41 | 15.93 | +9.3% | 16.64 | +4.6% |
| Net margin (%) | 25.9 | 29.3 | 25.7 |
Consolidated
- Filed with BSE
- 20 May 2022, 15:44 IST
- Board meeting
- 19 May 2022
- Period
- 01 Jan 2022 to 31 Mar 2022
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 20 May 2022, 15:44 IST
- Board meeting
- 19 May 2022
- Period
- 01 Jan 2022 to 31 Mar 2022
- Review status
- Audited
- Source
- XBRL filing on BSE